FDA 483 - Novartis Gene Therapies, Inc. - August 02, 2019

This FDA Form 483 document outlines several significant observations made during an inspection, indicating deficiencies in the facility's quality control and laboratory operations.

A primary observation notes a failure to thoroughly review unexplained discrepancies, even for batches already distributed. This suggests a potential gap in the quality system's ability to identify and address product quality issues post-release.

Furthermore, the inspection revealed that laboratory records are incomplete. Specifically, they do not include all data derived from tests, examinations, and assays necessary to ensure compliance with established specifications and standards. This indicates a lack of comprehensive documentation for quality assurance.

The responsibilities and procedures of the quality control unit are also not being fully followed, pointing to a systemic issue within the quality management system. This could lead to inconsistent application of quality standards and procedures.

Another critical finding is that laboratory records lack complete documentation of testing and standardization for laboratory reference standards. This omission could compromise the accuracy and reliability of analytical testing results.

Finally, the document states that established test procedures are not being followed. This non-adherence to defined protocols can lead to unreliable test outcomes and potentially affect product quality and safety.

In summary, the observations highlight issues across discrepancy investigations, laboratory data completeness, quality control unit adherence, reference standard documentation, and adherence to test procedures, all of which are critical for maintaining product quality and regulatory compliance.